在胰岛素生长因子三吸附后的Drastic Au(111) 表面重建
Vincent Humblot1, Anne Vallée, Ahmed Naitabdi
1Laboratoire de Réactivité de Surface, UMR CNRS 7197, Université Pierre et Marie Curie -UPMC Paris 6 case 178, 4 place Jussieu, 75005 Paris, France. vincent.humblot@upmc.fr
Journal of the American Chemical Society
|April 5, 2012
概括
胰岛素增长因子三分子的吸附在室温下动态重建黄金 (Au) 表面,不需要回火. 这项研究揭示了一种新的分子驱动的表面重组机制.
科学领域:
- 表面科学是一门学科.
- 材料科学 材料科学 材料科学
- 生物物理学的生物物理.
背景情况:
- 生物分子在金属表面的吸附通常形成2D有序层.
- 在室温下金属基板的重建是罕见的,通常需要化.
研究的目的:
- 为了研究胰岛素生长因子三吸附在Au111表面的影响.
- 探索由分子吸附驱动的室温表面重建.
主要方法:
- 扫描道显微镜 (STM) 用于可视化表面变化.
- 理论计算以了解分子层次的机制.
主要成果:
- 观察到Au(111) 表面的剧烈室温重建.
- 表面重建开始在扭曲和步骤边缘,也发生在无缺陷的露台上.
- 记录了动态和时间演变的重建过程.
结论:
- 胰岛素生长因子三分子可以在室温下诱导显著的Au(111) 表面重建.
- 观察到的重建是一个动态的过程,不需要热.
- 分子相互作用驱动金属表面形态的实质性变化.
相关概念视频
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

